EGFR and non-small cell lung carcinoma: Canadian Agency for Drugs and Technologies in Health (CADTH) recently conducted a review of the literature (11 observational studies) to assess the diagnostic performance of PCR-based methods to detect the presence of EGFR mutations in patients with advanced NSCLC [8].  The report concluded that PCR-based methods can identify mutations in EGFR with a similar sensitivity to that of direct sequencing.